Cost-Utility and Budget Impact Analysis for Stopping the Inappropriate Use of Proton Pump Inhibitors After Cessation of NSAID or Low-Dose Acetylsalicylic Acid Treatment (10.1007/s40266-019-00713-5, 2019)

被引:0
作者
Chau, Sek Hung [1 ]
Sluiter, Reinier Luuk [2 ]
Hugtenburg, Jacqueline Geertruida [1 ]
Wensing, Michel [3 ,4 ]
Kievit, Wietske [2 ]
Teichert, Martina [5 ]
机构
[1] Vrije Univ Amsterdam, Dept Clin Pharmacol & Pharm, Amsterdam Publ Hlth Res Inst, Amsterdam UMC, De Boelelaan 1117, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Geert Grootepl 21, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Sci Inst Qual Healthcare IQ Healthcare, Geert Grootepl 21, Nijmegen, Netherlands
[4] Heidelberg Univ, Dept Gen Practice & Hlth Serv Res, Neuenheimer Feld 130-3, Heidelberg, Germany
[5] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Albinusdreef 2, Leiden, Netherlands
关键词
D O I
10.1007/s40266-019-00719-z
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: In accordance with current guidelines, proton pump inhibitors (PPIs) are now generally prescribed as a protective co-medication in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose acetylsalicylic acid (LDASA). However, less attention is paid to the corresponding discontinuation of a PPI after cessation of NSAID or LDASA treatment. Objective: The aim of this study was to assess the extent of inappropriate PPI use, as the proportion of patients who started a PPI as a protective co-medication but continued using these drugs after cessation of NSAID and LDASA treatment. We also sought to estimate the potential cost savings and effect gains of discontinuing inappropriate PPI use and the resulting decrease in adverse effects and their detrimental consequences. Methods: Pharmacy dispensing data were used to map inappropriate PPI use in 2014 for community-dwelling patients. Strategies with or without PPI continuation were compared in the cost–utility analysis for a time horizon of 5 years from a healthcare perspective. Subsequently, incremental costs and effects (quality-adjusted life-years) were estimated with a Markov model. Results: Related to NSAID and LDASA treatment, 11.0% and 5%, respectively, of the PPI users were found to inappropriately continue PPI co-treatment. Discontinuation in 71- to 80-year-old patients suggested cost savings of €170.46 (95% confidence interval 75–282) at a 0.003 (95% confidence interval 0.001–0.005) quality-adjusted life-year increase. The total budget impact of stopping inappropriate PPI use related to NSAID/LDASA treatment in the Netherlands would amount to almost €1,050,000 after 1 year. Correspondingly, successful interventions to stop a patient’s inappropriate use would cost up to €29 and probably would pay for themselves in the following years. Conclusions: A substantial number of patients inappropriately continue to use a PPI after cessation of NSAID or LDASA treatment. Because adverse effects and their detrimental consequences are avoided, interventions to stop inappropriate PPI use, particularly in older patients, are likely to pay for themselves. © 2019, The Author(s).
引用
收藏
页码:75 / 75
页数:1
相关论文
共 1 条
[1]  
Chau SH, 2020, DRUG AGING, V37, P67, DOI 10.1007/s40266-019-00713-5